Immunological Targeting of CD133 in Recurrent Glioblastoma: A Multicenter Phase I Translational and Clinical Study of Autologous CD133 Dendritic Cell Immunotherapy.
JOURNAL OF CLINICAL ONCOLOGY（2017）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined